Federal contractor · SOUTH SAN FRANCISCO, CA

GENENTECH INC

No contract obligations recorded for GENENTECH INC in FY2026. Since FY2025: $1.1M. Its largest customer was Food and Drug Administration ($0).

Obligations · FY2026: $0
New awards: 1
Sole-source: —
Single offer: —

UEI: F7F8GZXL7Q93
Parent company: ROCHE HOLDING AG

Other than small businessForeign-owned

Open in the contracts explorer Relationship graph

Company family

Grouped from reported parent companies (UEI) and, where marked, AI judgments that two records name the same organization or group.

Part of the ROCHE DIAGNOSTICS CORPORATION company family: 6 registered entities, $109.2M in FY2026 together. See the family

ROCHE DIAGNOSTICS CORPORATIONINDIANAPOLIS, IN · Family page
Reported parent$89.1M
FOUNDATION MEDICINE, INC.CAMBRIDGE, MA
Reported parent$19.2M
GENENTECH USA, INCSOUTH SAN FRANCISCO, CA
Reported parent$939.6K
ROCHE MOLECULAR SYSTEMS, INC.PLEASANTON, CA
Reported parent$0
VENTANA MEDICAL SYSTEMS, INCTUCSON, AZ
Reported parent-$13.1K

Spending by fiscal year

Obligations per federal fiscal year (October–September).

1.1MFY2025
0FY2026

Top buying agencies

Obligations in FY2026.

Food and Drug Administration$00.0%
1 awards

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Largest awards

THIS PROJECT FOCUSES ON ADDRESSING CRITICAL CHALLENGES IN THE DESIGN AND ANALYSIS OF HYBRID RANDOMIZED CONTROLLED TRIALS (RCTS) IN LONGITUDINAL SETTINGS. THE FIRST GOAL IS TO DEVELOP CAUSAL METHODOLOGIES FOR MANAGING DIVERSE MISSING DATA PATTERNS IN$1.1M
Food and Drug Administration· Montgomery County, MD· Research & development· Sep 11, 2025 – Jun 11, 2026· 75F40125C00069

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

GENENTECH INC received $0 in federal assistance in FY2026, on 0 actions (0 new awards).

Assistance · FY2026: $0
New awards: 0
Actions: 0
Since FY2021: $299.7K

Assistance by fiscal year

256.3KFY2021
260.8KFY2022
0FY2023
-217.4KFY2025

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 7, 2026, loaded Oct 7, 2026 · FY2021–FY2025.

Teaming partners

Companies this company reported paying, primes that reported paying it, from FFATA subaward reports.

Companies it pays

No subawards reported to other companies.

Primes that pay it

5 companies · $547K reported

LEIDOS, INC.$181.5K
RESTON, VA · 1 subaward · Scientific research and development services
THE JOHNS HOPKINS UNIVERSITY APPLIED PHYSICS LABORATORY LLC$178.4K
LAUREL, MD · 3 subawards · Scientific research and development services
CHEMONICS INTERNATIONAL, INC.$127.7K
ARLINGTON, VA · 1 subaward · Management, scientific, and technical consulting services

Showing the top 3 of each list. Open the profile for potential partners and the full lists.

Primes report first-tier subawards of $30,000 or more themselves, and many go unreported (GAO-24-106214). Reporting moved from FSRS to SAM.gov in March 2025 and fewer sub-contracts have been reported since. Amounts are what primes reported; they are never added to prime award totals.

Source: Subawards (first-tier sub-contracts and sub-grants reported under FFATA) (U.S. Department of the Treasury, USAspending.gov (reports filed in SAM.gov, formerly FSRS)), data current to Oct 7, 2026, loaded Oct 7, 2026 · Subawards loaded from 2021.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 45 markets (agency × industry), FY2024–FY2026.

MERCK SHARP & DOHME LLC$163.2M−82% in FY2026
RAHWAY, NJ · 2 entities · 29% of this company's obligations are in markets they both serveOffice of Assistant Secretary for Preparedness and Response · Pharmaceutical and medicine manufacturingVeterans Affairs · Pharmaceutical and medicine manufacturing
ELUSYS THERAPEUTICS INC$123.9M−100% in FY2026
PARSIPPANY, NJ · 27% of this company's obligations are in markets they both serveOffice of Assistant Secretary for Preparedness and Response · Pharmaceutical and medicine manufacturing
PHLOW CORP.$204.8M+1,158% in FY2026
RICHMOND, VA · 29% of this company's obligations are in markets they both serveOffice of Assistant Secretary for Preparedness and Response · Pharmaceutical and medicine manufacturing

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 7, 2026, loaded Oct 7, 2026 · FY2024–FY2026.

Lobbying and PAC activity

Organizations in House lobbying disclosures and FEC records whose names an AI judgment matched to this company. Those records carry no identifier shared with contracts, so every match is by name.

Across the company family of ROCHE DIAGNOSTICS CORPORATION (6 recipients).

Matched organizations

Foundation Medicine, Inc.AI match · 100%
GENENTECH INC.AI match · 100%
Genentech USA, Inc.AI match · 100%
ROCHE DIAGNOSTICS CORPORATIONAI match · 100%

Lobbying · 2025: $10.7M; 102 reports
Lobbying · 2023–2026: $35.9M; $35.9M in its own reports
PAC giving · 2026: $404.5K; 2 PACs

Lobbying by year

2023$9.9M
103 reports
2024$9.5M
96 reports
2025$10.7M
102 reports
2026$5.8M
51 reports

Top issues

Health issues255 reports
Medicare and Medicaid181 reports
Budget and appropriations59 reports
Taxation and the Internal Revenue Code55 reports
Copyright, patent and trademark51 reports
Pharmacy46 reports
Trade (domestic and foreign)46 reports
Manufacturing28 reports

Who was contacted

U.S. HOUSE OF REPRESENTATIVES293 reports
U.S. SENATE282 reports
Health & Human Services - Dept of (HHS)49 reports
Food & Drug Administration (FDA)33 reports
Centers For Medicare and Medicaid Services (CMS)29 reports
U.S. Trade Representative (USTR)20 reports
Homeland Security - Dept of (DHS)18 reports
Treasury - Dept of16 reports
White House Office16 reports
Labor - Dept of (DOL)14 reports

Houses of Congress and federal agencies the reports list as contacted (a report names every one for all its issues).

Lobbying firms hired

Tarplin, Downs & Young, LLC$2M
28 reports
The McManus Group$990K
22 reports
OGR$960K
14 reports
Tiber Creek Group$840K
14 reports
Tiber Creek Health Strategies, Inc.$840K
14 reports
Todd Strategy Group$840K
14 reports
MARSHALL & POPP, LLC$840K
14 reports
Capitol Counsel LLC$720K
14 reports

28 firms in all. Registrants who are individuals are counted, not named.

PAC giving to candidates by party, 2026 cycle

Democratic$221.5K55%
Republican$182K45%
Other or none$1,0000.2%

PACs sponsored

GENENTECH INC. POLITICAL ACTION COMMITTEE (GENENPAC)$757.9K raised this cycle
ROCHE DIAGNOSTICS CORPORATION PAC (ROCHE DXPAC)$150.7K raised this cycle

PACs these organizations sponsor (connected organizations in FEC records). A PAC gives employees' and members' voluntary contributions, not the company's own money.

Lobbying amounts are the filers' own good-faith estimates on quarterly LD-2 reports (the law asks for amounts rounded to $10,000; under $5,000 need not be itemized), latest amendment only. When an organization files its own report, it replaces what outside firms report for it that quarter. Matches are by name. Lobbying and political giving are legal and public: they show engagement with government, not influence over any award. Correlation is not influence: these organizations' lobbying and their contracts are shown side by side, and nothing here implies either affected the other.

Source: Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives), data current to Oct 7, 2026, loaded Oct 7, 2026 · 2023–2026.

Source: Committees, candidates and committee contributions to candidates (Federal Election Commission), data current to Oct 7, 2026, loaded Oct 7, 2026 · 2026, 2024, 2022.

Matches: Analisa AI name judgments (entity-match@1), updated Oct 5, 2026.

Congress: members and bills

Through the organizations matched to this company: members of Congress whose campaigns received contributions from their PACs, and the bills their lobbying reports named. Shown beside the company's contracts as a comparison, not a cause.

Members whose campaigns received from its PACs, 2026 cycle

Donald G. Davis$10K
D-NC-1 · House · 1 PAC
Brett Guthrie$10K
R-KY-2 · House · 2 PACs
Adam Gray$10K
D-CA-13 · House · 1 PAC
John Joyce$10K
R-PA-13 · House · 2 PACs
Mariannette Miller-Meeks$10K
R-IA-1 · House · 2 PACs
Nanette Diaz Barragán$9,500
D-CA-44 · House · 2 PACs
Kim Schrier$9,000
D-WA-8 · House · 1 PAC
Troy A. Carter$8,500
D-LA-2 · House · 1 PAC
H. Morgan Griffith$8,500
R-VA-9 · House · 2 PACs
Jake Auchincloss$8,000
D-MA-4 · House · 2 PACs

$403.5K of the $404.5K its PACs gave to federal candidates went to 118 members of Congress.

Members whose campaigns received from its PACs, 2024 cycle

Lisa Blunt Rochester$10K
D-DE · Senate · 1 PAC
Earl L. "Buddy" Carter$10K
R-GA-1 · House · 2 PACs
Donald G. Davis$10K
D-NC-1 · House · 1 PAC
Richard Hudson$10K
R-NC-9 · House · 2 PACs
Diana DeGette$9,500
D-CO-1 · House · 2 PACs

Direct and in-kind contributions the members' campaigns received (FEC), net of refunds. Party and seat are the member's current or latest.

Bills named in its lobbying reports

H.R. 3290 · 340B Transparency Act15 reports
118th Congress · Reported by committee · 2023–2024
H.R. 2369 · VALID Act of 202313 reports
118th Congress · Introduced · 2023–2024
H.R. 1492 · To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.13 reports
119th Congress · Introduced · 2025–2026
H.R. 5376 · Inflation Reduction Act of 202212 reports
117th Congress · Became law · 2023–2024
H.R. 5378 · Lower Costs, More Transparency Act12 reports

Amounts, members and bills are as recorded, shown side by side. They say nothing about why a contribution was made, how a member voted or what a report sought. A bill number written in a report is read as the measure of the Congress its context points to (a law's number, the Congress written next to it, the title), else of the Congress then sitting.

Source: Committees, candidates and committee contributions to candidates (Federal Election Commission), data current to Oct 7, 2026, loaded Oct 7, 2026.

Source: Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives), data current to Oct 7, 2026, loaded Oct 7, 2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 7, 2026, loaded Oct 7, 2026.